RIST: A potent new combination therapy for glioblastoma

Small-Molecule XIAP Inhibitors Enhance γ-Irradiation-Induced Apoptosis in Glioblastoma

(2015) Sri Hari Krishna Vellanki et al.   NEOPLASIA

Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo

(2015) Bastianina Canu et al.   NEOPLASIA

Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines

(2014) Georg Karpel-Massler et al.   Anti-Cancer Agents in Medicinal Chemistry

Temozolomide Modifies Caveolin-1 Expression in Experimental Malignant Gliomas In Vitro and In Vivo

(2014) Céline Bruyère et al.   Translational Oncology

Inhibition of NF- B Signaling Ablates the Invasive Phenotype of Glioblastoma

(2013) M.-A. Westhoff et al.   MOLECULAR CANCER RESEARCH

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

(2012) Edward Pan et al.   JOURNAL OF NEURO-ONCOLOGY

Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin

(2012) Keita Saito et al.   PLoS One

Antiangiogenic Agent Sunitinib Transiently Increases Tumor Oxygenation and Suppresses Cycling Hypoxia

(2011) S. Matsumoto et al.   CANCER RESEARCH

Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery In Vivo

(2011) N. Qayum et al.   CLINICAL CANCER RESEARCH

Glioblastoma survival in the United States before and during the temozolomide era

(2011) Derek R. Johnson et al.   JOURNAL OF NEURO-ONCOLOGY

Treatment of high-grade glioma in children and adolescents

(2011) T. J. MacDonald et al.   NEURO-ONCOLOGY

Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors

(2010) K. A. Edgar et al.   CANCER RESEARCH

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

(2010) D. Koul et al.   NEURO-ONCOLOGY

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib

(2010) Manik Chahal et al.   NEURO-ONCOLOGY

mTOR signaling in glioblastoma: lessons learned from bench to bedside

(2010) D. Akhavan et al.   NEURO-ONCOLOGY

U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line

(2010) Michael James Clark et al.   PLoS Genetics

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

(2009) Jennifer A. Quinn et al.   JOURNAL OF NEURO-ONCOLOGY

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

(2009) F. I. Raynaud et al.   MOLECULAR CANCER THERAPEUTICS

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair

(2009) M -A Westhoff et al.   ONCOGENE

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- and Drug-Induced Apoptosis

(2008) D. Opel et al.   CANCER RESEARCH

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

(2008) Qingyu Zhou et al.   NEURO-ONCOLOGY

Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells

(2008) M A Westhoff et al.   ONCOGENE